Skip to main content

Table 1 Patient characteristics

From: Laser Doppler blood flowmeter as a useful instrument for the early detection of lower extremity peripheral arterial disease in hemodialysis patients: an observational study

 Non-PAD (n = 106)PAD (n = 22)p
Age (year)59.8(50.0, 70.0)71.8(64.0,81.0)0.0004
Dialysis Vintage (years)7.0(3.0, 14.0)9.0(7.0, 11.0)NS
BMI (kg/m2)23.2±4.422.1±4.5NS
 YesNo YesNo  
DM (y/n %)307628.30%13959.10%0.0115
Sex (male/female)198782.10%41881.80%NS
SBP (mmHg)149.3±21.3146.2±21.9NS
DBP (mmHg)81±13.771.3±13.50.0056
Online HDF (y/n)1610615.10%32213.60%NS
Total Fluid Removal (kg)3.32.73.82.62.23.40.0134
KtV1.4(1.4, 1.5)1.41.31.50.893
CGR (%)104.8(100.0, 109.6)86.3(78.3, 94.3)0.0002
nPCR (g/kg/day)0.9(0.9, 1.0)0.8(0.8, 0.9)0.006
Anticoagulant for dialysis n (%)HepalineLow MolecularNafamostatHepalineLow MolecularNafamostat 
 77 / 72.6%22 / 20.8%6 / 5.7%11 / 50.0%7 / 31.8%6 / 5.7% 
Fontaine grade I n (%)99 93.40%8 36.40% 
Fontaine grade II n (%)7 6.60%3 13.60% 
Fontaine grade III n (%)0 0%5 22.70% 
Fontaine grade IV n (%)0 0%6 27.30% 
Hb (g/dL)11.2±0.910.8±1.2NS
Ht (%)34.5±2.834±4.0NS
Fe (μg/dL)76.1±22.561.7±22.20.0114
Ferritin (ng/mL)41.5(20.3, 81.7)60.3(28, 106.3)NS
TSAT (%)26.8(21.7, 33.9)24.3(16.5, 29.8)NS
BUN (mg/dL)68.2(65.5, 70.9)58.6(51.8, 65.4)0.0111
Cr (g/dL)12.5(11.9, 13.0)9.5(8.5, 10.5)< 0.0001
UA (mg/dL)7.6(6.6, 8.5)7.2(5.6, 7.9)0.0326
CRP (ng/mL)0.2(0.1, 0.4)0.5(0.1, 1.2)0.0104
Na (mEq/L)139.2(137.3, 140.5)137.5(136.2, 139.2)NS
K (mEq/L)4.9(4.5, 5.2)4.4(4.2, 4.8)0.004
Cl (mEq/L)101.7(100,0103.3)101.7(100, 104.0)NS
Pi (mg/dL)5.6(5.4, 5.9)5.1(4.6, 5.7)0.1148
Ca (mg/dL)8.5(8.1, 9.2)8.2(7.9, 8.6)NS
iPTH (pg/mL)254.5(224.4, 284.7)264.9(194.2, 335.6)0.7828
Alb (g/mL)3.7(3.6, 3.7)3.3(3.1, 3.5)0.0003
Ret (%0)16.1(15, 17.1)16.8(13.5, 20.1)0.6495
TP (g/dL)7.0(6.7, 7.2)6.9(6.7, 7.3)NS
Tcho (mg/dL)164.9(158.7, 171.2)137.8(127.1, 148.4)< 0.0001
TG (mg/dL)143.1(125.0, 161.3)94.7(74.3, 115.2)0.0006
LDL (mg/dL)88.0(74.0, 114.5)68.3(58.8, 82.3)0.003
HDL (mg/dL)47.9(45.1, 50.7)45.8(39.7, 51.9)0.5126
β2MG (mg/L)28.1(26.9, 29.2)31.1(28.1, 34.1)0.061
ESA dose (μg/week)6.6(3.0, 10.0)11.3(4.2, 17.8)NS
Vitamin D (μg/week)0.0(0.0, 2.5)0.0(0.0, 2.5)NS
Cinacalcet (mg/week)0.0(0.0350.0)87.5(0.0350.0)NS
 YesNoYes (%)YesNoYes (%) 
Ca antagonist (y/n)624458.50%51722.70%0.0041
ACE/ARB (y/n)307628.30%51722.70%NS
Alpha blocker (y/n)51014.70%2209.10%NS
Alpha beta blocker (y/n) + B35357130.00%61627.30%NS
Aspirin (y/n)218519.80%91340.90%0.0506
Ticlopidine hydrochloride (y/n)31032.80%0220.00%NS
Clopidogrel sulfate (y/n)8987.60%41818.20%NS
Cilostazol (y/n)11050.90%31913.60%0.016
  1. Systolic Bp, Alb, Cr, and other covariates were decreased in the PAD group.
  2. SPP skin perfusion pressure, LDF laser Doppler flowmetry, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, Hb hemoglobin, HT hypertension, TSAT transferrin saturation, BUN blood urea nitrogen, Cr creatinine, UA uric acid, CRP C-reactive protein, iPTH intact parathyroid hormone, Alb albumin, TP total protein, Tcho total cholesterole, TG triglycerides, LDL low-density lipoprotein, HDL high-density lipoprotein, β2MG beta-2 microglobulin, KtV measure of dialysis, CGR creatinine generation rate, nPCR normalized protein catabolic rate, ESA erythropoiesis-stimulating agent, DM diabetes mellitus, ACE angiotensin-converting enzyme, inhibitor, ARB angiotensin receptor blocker, NS not significant, y/n yes/no.
  3. Data are presented as n(%), mean ± sd, or median (interquartile range)